Department of Pharmacy, Health and Nutrition Sciences, University of Calabria, Rende, Italy.
Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Pharmacol Res Perspect. 2021 Feb;9(1):e00691. doi: 10.1002/prp2.691.
Coronaviruses represent global health threat. In this century, they have already caused two epidemics and one serious pandemic. Although, at present, there are no approved drugs and therapies for the treatment and prevention of human coronaviruses, several agents, FDA-approved, and preclinical, have shown in vitro and/or in vivo antiviral activity. An in-depth analysis of the current situation leads to the identification of several potential drugs that could have an impact on the fight against coronaviruses infections. In this review, we discuss the virology of human coronaviruses highlighting the main biological targets and summarize the current state-of-the-art of possible therapeutic options to inhibit coronaviruses infections. We mostly focus on FDA-approved and preclinical drugs targeting viral conserved elements.
冠状病毒代表着全球健康威胁。在本世纪，它们已经引发了两次大流行和一次严重的大流行。尽管目前还没有批准的药物和疗法来治疗和预防人类冠状病毒，但一些已在体外和/或体内显示出抗病毒活性的药物、FDA 批准的和临床前的药物已经出现。对当前形势的深入分析导致确定了几种可能对抗冠状病毒感染产生影响的潜在药物。在这篇综述中，我们讨论了人类冠状病毒的病毒学，强调了主要的生物靶点，并总结了目前抑制冠状病毒感染的可能治疗选择的最新进展。我们主要关注针对病毒保守元件的 FDA 批准药物和临床前药物。
